ESR1 and invasive breast carcinoma: Furthermore, our analyses also provide promising kinase–substrate node and edge biomarkers for clinically relevant refinement of prognostic assessment in the ER-positive and ER-negative subtypes, and these biomarkers also serve as candidate drug targets for the treatment of breast invasive cancer in the future.